Nature Search

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes

Clifford M. Csizmar
Anuya Natu
Mrinal M. Patnaik
Research24 Jun 2025
Leukemia

P: 1-5
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort

Mithun Vinod Shah
Kevin Hung
Devendra Hiwase
ResearchOpen Access07 May 2025
Blood Cancer Journal

Volume: 15, P: 1-11
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity

Talha Badar
Yenny A. Moreno Vanegas
Mrinal M. Patnaik
ResearchOpen Access21 Sept 2023
Blood Cancer Journal

Volume: 13, P: 1-7
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Naseema Gangat
Kebede H. Begna
Ayalew Tefferi
ResearchOpen Access04 Jan 2023
Blood Cancer Journal

Volume: 13, P: 1-7
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients

Abhishek A. Mangaonkar
Terra L. Lasho
Rami Komrokji
ResearchOpen Access01 Feb 2022
Blood Cancer Journal

Volume: 12, P: 1-6
Mayo Clinic experience with 1123 adults with acute myeloid leukemia

Kebede H. Begna
Walid Ali
Ayalew Tefferi
ResearchOpen Access02 Mar 2021
Blood Cancer Journal

Volume: 11, P: 1-8
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms

Mahmoud Yacout
Bahga Katamesh
Aref Al-Kali
ResearchOpen Access23 Sept 2024
Leukemia

Volume: 38, P: 2727-2730
Momelotinib therapy for myelofibrosis: a 7-year follow-up

Ayalew Tefferi
Daniela Barraco
Animesh Pardanani
ResearchOpen Access07 Mar 2018
Blood Cancer Journal

Volume: 8, P: 1-5
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia

The oncogenic fusion protein AML1-ETO has the ability of AML1 to interact with DNA but blocks AML1-dependent transcription. Here the authors report that histone lysine methyltransferase EZH1 interacts with AML1-ETO and methylates AML1-ETO at lysine 43, promoting AML1-ETO transcriptional repression in leukemia.

Liping Dou
Fei Yan
Li Yu
ResearchOpen Access07 Nov 2019
Nature Communications

Volume: 10, P: 1-15
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome

Aref Al-Kali
Ahmad Nanaa
Hassan B. Alkhateeb
CorrespondenceOpen Access10 Apr 2023
Blood Cancer Journal

Volume: 13, P: 1-4
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study

Douglas Tremblay
Clifford Csizmar
Guillermo Montalban-Bravo
Research12 Nov 2024
Leukemia

Volume: 39, P: 257-260
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)

Mark Gurney
Abhishek A. Mangaonkar
Mrinal M. Patnaik
Research08 Jul 2023
Leukemia

Volume: 37, P: 1753-1756
A dynamic N⁶-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors

Fei Yan
Aref Al-Kali
Shujun Liu
ResearchOpen Access08 Oct 2018
Cell Research

Volume: 28, P: 1062-1076
Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia

Connor Walsh
Anthony Hunter
Mrinal M. Patnaik
Research29 Mar 2022
Leukemia

Volume: 36, P: 1693-1696
Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis

Rong He
Daniel J. Devine
David S. Viswanatha
Amendments and CorrectionsOpen Access07 Oct 2019
Modern Pathology

Volume: 33, P: 514
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients

Abhishek A. Mangaonkar
David M. Swoboda
Mrinal M. Patnaik
Research11 Sept 2019
Leukemia

Volume: 34, P: 656-661
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms

Mithun Vinod Shah
Abhishek A. Mangaonkar
Dong Chen
ResearchOpen Access08 Jul 2022
Blood Cancer Journal

Volume: 12, P: 1-9
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

David P. Steensma
Martin Wermke
Uwe Platzbecker
ResearchOpen Access25 Jun 2021
Leukemia

Volume: 35, P: 3542-3550
One thousand patients with essential thrombocythemia: the Mayo Clinic experience

Naseema Gangat
Omer Karrar
Ayalew Tefferi
ResearchOpen Access18 Jan 2024
Blood Cancer Journal

Volume: 14, P: 1-11
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

Maymona G. Abdelmagid
Aref Al-Kali
Ayalew Tefferi
ResearchOpen Access11 Aug 2023
Blood Cancer Journal

Volume: 13, P: 1-9
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

Mithun Vinod Shah
Elizabeth Ngoc Hoa Tran
Devendra K. Hiwase
ResearchOpen Access11 Apr 2023
Blood Cancer Journal

Volume: 13, P: 1-9
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation

Maansi Joshi
Joselle Cook
Hassan B. Alkhateeb
CorrespondenceOpen Access04 Mar 2021
Blood Cancer Journal

Volume: 11, P: 1-4
Isolated anemia in patients with large granular lymphocytic leukemia (LGLL)

Youssef Salama
Fang Zhao
Min Shi
ResearchOpen Access22 Feb 2022
Blood Cancer Journal

Volume: 12, P: 1-7
Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study

Zhuoer Xie
Ahmad Nanaa
Aref Al-Kali
CorrespondenceOpen Access01 Mar 2021
Blood Cancer Journal

Volume: 11, P: 1-5
Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience

Ahmad Nanaa
David Viswanatha
Aref Al-Kali
CorrespondenceOpen Access30 Jun 2021
Blood Cancer Journal

Volume: 11, P: 1-4
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant

Ayalew Tefferi
Animesh Pardanani
Naseema Gangat
CorrespondenceOpen Access19 Mar 2024
Blood Cancer Journal

Volume: 14, P: 1-4
EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant

Anmol Baranwal
Abhishek Mangaonkar
Hassan B. Alkhateeb
CorrespondenceOpen Access13 Jan 2024
Bone Marrow Transplantation

Volume: 59, P: 558-560
Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis

Rong He
Daniel J. Devine
David S. Viswanatha
ResearchOpen Access30 Aug 2019
Modern Pathology

Volume: 33, P: 334-343
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Mostafa Abdallah
Kristen McCullough
Naseema Gangat
CorrespondenceOpen Access13 Mar 2023
Blood Cancer Journal

Volume: 13, P: 1-4
Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia

Anmol Baranwal
Ahmad Nanaa
Hassan B. Alkhateeb
CorrespondenceOpen Access20 Aug 2022
Bone Marrow Transplantation

Volume: 57, P: 1716-1718
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Hassan B. Alkhateeb
Razan Mohty
Mithun Vinod Shah
CorrespondenceOpen Access26 Jul 2022
Blood Cancer Journal

Volume: 12, P: 1-5
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

Ahmad Ghorab
Aref Al-Kali
Talha Badar
CorrespondenceOpen Access24 Jun 2022
Blood Cancer Journal

Volume: 12, P: 1-4
Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients

Rong He
Jonathan Chiou
David S. Viswanatha
CorrespondenceOpen Access25 Jan 2022
Blood Cancer Journal

Volume: 12, P: 1-4
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia

Paul J. Hampel
Sameer A. Parikh
Wei Ding
CorrespondenceOpen Access02 Mar 2021
Blood Cancer Journal

Volume: 11, P: 1-6
A population-based study of chronic neutrophilic leukemia in the United States

Gordon J. Ruan
Caleb J. Smith
Mithun V. Shah
CorrespondenceOpen Access15 Jun 2020
Blood Cancer Journal

Volume: 10, P: 1-4
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia

Prateek Pophali
Aasiya Matin
Mrinal M. Patnaik
CorrespondenceOpen Access20 Nov 2020
Blood Cancer Journal

Volume: 10, P: 1-6
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts

Abhishek A. Mangaonkar
Terra L. Lasho
Mrinal M. Patnaik
CorrespondenceOpen Access12 Feb 2018
Blood Cancer Journal

Volume: 8, P: 1-4
Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms

Mrinal M. Patnaik
Terra Lasho
Eric Solary
CorrespondenceOpen Access22 Aug 2018
Blood Cancer Journal

Volume: 8, P: 1-5

Search

Filter By:

Search

Quick links